Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Contralateral Axillary Lymph Node Metastases Detected by Repeat Sentinel Lymph Node Biopsy in a Patient with Ipsilateral Breast Tumor Recurrence: A Case Report.

Created on 26 Oct 2026

Authors

Naotaka Uchida, Takako Suda

Published in

Surgical case reports. Volume 12. Issue 1. Epub Oct 22, 2026.

Abstract

There is no consensus on the significance of repeat sentinel lymph node (SLN) biopsy in a patient with ipsilateral breast tumor recurrence (IBTR).
A 49-year-old premenopausal woman developed an ipsilateral breast cancer (BC) lesion after previously undergoing lumpectomy, SLN biopsy, and adjuvant radiation therapy for left-sided lobular carcinoma in situ at the age of 35. Because of the contralateral SLNs identified on radioisotope lymphoscintigraphy, we decided to perform a left mastectomy with contralateral axillary lymph node dissection. Intraoperative SLN mapping using indigo carmine was negative. A total of 3 contralateral axillary lymph node metastases, all sentinel nodes, were identified among 18 resected nodes. Because this patient's second BC was an invasive ductal carcinoma, a different histology from her first tumor, we diagnosed a new primary BC along with contralateral axillary lymph node metastases and planned adjuvant therapy accordingly.
Repeat SLN biopsy for IBTR plays a key role in determining accurate SLN status and in optimizing adjuvant therapy.

PMID:
42928951
Bibliographic data and abstract were imported from PubMed on 26 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 10
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement